Tenax Therapeutics (TENX) Net Income towards Common Stockholders (2010 - 2026)

Tenax Therapeutics (TENX) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$85.6 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 722.52% year-over-year to -$85.6 million; the trailing twelve-month figure through Mar 2026 stood at -$138.8 million (down 473.17% YoY), and the FY2025 full-year result was -$102.9 million, down 73.66% from the prior year.
• Net Income towards Common Stockholders retreated to -$85.6 million in Q1 2026, from -$15.5 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $2.7 million in Q3 2022 to a low of -$85.6 million in Q1 2026.
• A 5-year average of -$10.3 million and a median of -$3.8 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders jumped 104.1% in 2022 and slumped 722.52% in 2026, its largest moves.
• Tracing TENX's Net Income towards Common Stockholders over 5 years: stood at $2.6 million in 2022, then sank by 580.66% to -$12.3 million in 2023, then soared by 48.96% to -$6.3 million in 2024, then plunged by 147.82% to -$15.5 million in 2025, then slumped by 451.31% to -$85.6 million in 2026.
• Business Quant data shows TENX's Net Income towards Common Stockholders at -$85.6 million in Q1 2026, -$15.5 million in Q4 2025, and -$26.8 million in Q3 2025.